XML 73 R63.htm IDEA: XBRL DOCUMENT
v3.21.2

COMMITMENTS AND CONTINGENCIES (Details) $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Apr. 30, 2020 agreement plaintiff | Dec. 31, 2019 USD ($) opposingParty patent | Sep. 30, 2021 USD ($) | Sep. 30, 2021 USD ($) plaintiff lawsuit | Dec. 31, 2016 party
Loss Contingencies [Line Items] |  |  |  |  |
Litigation accrual reversed | $ |  |  | $ 175 |  |
Number of patents challenged, scenario one | patent |  | 4 |  |  |
Number of patents challenged, scenario two | patent |  | 2 |  |  |
Juno Therapeutics, Inc. and Sloan Kettering Cancer Center |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Damages awarded | $ |  | $ 585 |  |  |
Running royalty rate from October 2017 |  | 27.60% |  |  |
Enhancement rate on past damages | 50.00% |  |  |  |
Running royalty rate on future sales | 27.60% |  |  |  |
ViiV Healthcare Company | Pending Litigation |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Damages amount | $ |  |  |  | $ 16,400 |
Pre-Exposure Prophylaxis |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Number of material transfer agreements | agreement | 4 |  |  |  |
European Patent Claims 2024 Expiration |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Number of parties appealed |  | 2 |  |  |
European Patent Claims 2026 Expiration |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Number of parties appealed |  | 3 |  |  |
European Patent Claims 2032 Expiration |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Number of parties appealed |  | 3 |  |  |
European Patent Claims 2027 Expiration |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Number of parties appealed |  | 2 |  |  |
Number of parties filing opposition | party |  |  |  |  | 3
Product Liability |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Number of class action lawsuits | lawsuit |  |  |  | 1 |
Number of plaintiffs involved | plaintiff |  |  |  | 24,000 |
Qui Tam |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Number of plaintiffs involved | plaintiff | 2 |  |  |  |

X
- Definition Judgment: Enhanced Damages On Past Sales + References No definition available. + Details
Name: | gild_JudgmentEnhancedDamagesOnPastSales
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Judgment: Royalty Rate from October 2017 + References No definition available. + Details
Name: | gild_JudgmentRoyaltyRateFromOctober2017
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Judgment: Royalty Rate on Future Sales + References No definition available. + Details
Name: | gild_JudgmentRoyaltyRateOnFutureSales
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Material Transfer Agreements, Number + References No definition available. + Details
Name: | gild_LossContingencyMaterialTransferAgreementsNumber
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Parties Appealed, Number + References No definition available. + Details
Name: | gild_LossContingencyPartiesAppealedNumber
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Parties Filing Opposition, Number + References No definition available. + Details
Name: | gild_LossContingencyPartiesFilingOppositionNumber
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Patents Allegedly Infringed, Number, Scenario One + References No definition available. + Details
Name: | gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two + References No definition available. + Details
Name: | gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in loss contingency liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of damages awarded to the plaintiff in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The total number of new claims filed pertaining to a loss contingency during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 + Details
Name: | us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of plaintiffs that have filed claims pertaining to a loss contingency. + References No definition available. + Details
Name: | us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_EuropeanPatentClaims2024ExpirationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_EuropeanPatentClaims2026ExpirationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_EuropeanPatentClaims2027ExpirationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_ProductLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_QuiTamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |